drugset / Trial / NCT03305224
The Combination Therapy With Ra-223 and Enzalutamide
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Timeline
- Start
- 2017-10-27
- Primary completion
- 2021-10-30
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | — |
| Subject | Ra223 | Unknown | 0.055 mbq/kg | Intravenous |